Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease | NEJM
Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn …
Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn …
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
NAFLD is a spectrum of progressive liver disease that encompasses simple steatosis,
NASH, fibrosis and, ultimately, cirrhosis. NAFLD is recognized as the hepatic component of …
NASH, fibrosis and, ultimately, cirrhosis. NAFLD is recognized as the hepatic component of …
Nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a disorder characterized by excess accumulation
of fat in hepatocytes (nonalcoholic fatty liver (NAFL)); in up to 40% of individuals, there are …
of fat in hepatocytes (nonalcoholic fatty liver (NAFL)); in up to 40% of individuals, there are …
[PDF][PDF] The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
P Angulo, JM Hui, G Marchesini, E Bugianesi… - …, 2007 - Wiley Online Library
Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis are at the
highest risk for progressing to end‐stage liver disease. We constructed and validated a …
highest risk for progressing to end‐stage liver disease. We constructed and validated a …
Steatohepatitis: a tale of two “hits”?
Steatohepatitis: A tale of two “hits”? - ScienceDirect Skip to main contentSkip to article
Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue …
Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue …
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
Summary Background The cytochrome P450 CYP2C9 is responsible for the metabolism of S-
warfarin. Two known allelic variants CYP2C9* 2 and CYP2C9* 3 differ from the wild type …
warfarin. Two known allelic variants CYP2C9* 2 and CYP2C9* 3 differ from the wild type …
QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.
CP Day, JM McComb, RW Campbell - Heart, 1990 - heart.bmj.com
Homogeneity of recovery time protects against arrhythmias whereas dispersion of recovery
time is arrhythmogenic. A single surface electrocardiographic QT interval gives no …
time is arrhythmogenic. A single surface electrocardiographic QT interval gives no …
[HTML][HTML] Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030
C Estes, QM Anstee, MT Arias-Loste, H Bantel… - Journal of …, 2018 - Elsevier
Background & Aims Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic
steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma …
steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma …
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
Drug-induced liver injury (DILI) is an important cause of serious liver disease. The
antimicrobial agent flucloxacillin is a common cause of DILI, but the genetic basis for …
antimicrobial agent flucloxacillin is a common cause of DILI, but the genetic basis for …
[PDF][PDF] Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
IN Guha, J Parkes, P Roderick, D Chattopadhyay… - …, 2008 - Wiley Online Library
The detection of fibrosis within nonalcoholic fatty liver disease (NAFLD) is important for
ascertaining prognosis and the stratification of patients for emerging therapeutic …
ascertaining prognosis and the stratification of patients for emerging therapeutic …